// App-Quantinova.ai

545 : A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 (cisplatin, vinblastine) in early stage breast cancer: the INVINCIBLE trial

Researchers

Presenter

  • Angel Arnaout

Principal Investigators

  • Susan Robertson

  • Kianoosh Keyhanian

  • Arif Awan

  • Gregory Pond

  • John Bartlett

  • Megan Hopkins

  • Linda Liao

  • Vida Talebian

  • Lazlo Radvyani

  • Lewis Bender

  • Ian Walters

  • Vanessa Lopez Ozuna

  • Melanie Spears

Medical Centers

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • McMaster University, Hamilton, ON, Canada

  • University of Edinburgh, Edinburgh, UK

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Intensity Therapeutics, Westport, CT, United States

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Vinblastine

  • Cisplatin

  • Cisplatin/vinblastine formulation with cell penetration enhancer

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved